The post TKI/Immunotherapy & side effect management Webinar – Watch Again appeared first on Kidney Cancer UK ..read more

The post Get Involved, Fundraise For Kidney Cancer UK appeared first on Kidney Cancer UK ..read more

Our Coffee, Cake & Chat Zoom meetings continue to offer regular online support groups to patients their families and carers across the UK. Join us on your laptop, iPad or mobile phone via our Zoom Link and bring a drink, cake and your usual helpful chat so that others can learn from your experiences. All events are held on Zoom. We understand that setting this up can seem daunting for some, so get in touch and we can guide you through the simple process. Please note; There is a limit to 10 people per session, however if we receive a high demand extra sessions will be added. Upcoming Dates ..read more

The post Webinar – TKI/Immunotherapy and side effect management appeared first on Kidney Cancer UK ..read more

A cancer patient from West Yorkshire has become the first person in the world to have a kidney tumour removed using sonic beams. Anthony Harris, 73, agreed to be a “guinea pig” for the groundbreaking treatment, called histotripsy, at Leeds Cancer Centre. Mr Harris, of Castleford, had an overnight stay in hospital following the non-invasive procedure before being allowed home. He said: “I was quite honoured to be the first person in the world to receive this treatment at the hospital. “From the minute I went to see the doctor last December, the ball has moved really fast. I’m hopeful about ..read more

Howden Coffee partners with Kidney Cancer UK to make a difference with coffee Howden Coffee, a UK coffee specialist, has announced a collaboration with Kidney Cancer UK to donate 5% of its customers’ orders to Kidney Cancer UK that supports their mission, patients, and operations. The collaboration between Howden Coffee and Kidney Cancer UK has been established so that coffee lovers can directly contribute to the amazing work undertaken by Kidney Cancer UK while getting a quality coffee fix. With Kidney cancer being the fifth most common cancer in men and tenth most in women, the support is es ..read more

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy Single Infusion of ALLO-316 Demonstrates Promising Anti-Tumor Activity in CD70 Expressing RCC Three of 10 Patients Achieved Partial Response Disease Control Rate of 100% in CD70 Expressing RCC Proprietary Dagger™ Technology, a component of Investigational ALLO-316, Is Designed to Confer Resistance to Allogeneic CAR T Cell Rejection and Contributes to Improved Cell Expansion and Persistence in Patients ..read more

Kidney Cancer UK and Kidney Cancer Scotland are pleased to announce that their new Chief Executive Officer will be Malcolm Packer. Packer has worked with Kidney Cancer UK since 2007 on a freelance, voluntary basis and on a permanent part time basis since 2013 as Head of Charity Affairs and Communications. His achievements include establishing the Kidney Cancer UK Annual Patient Survey, which is approaching its tenth year; running Kidney Cancer Awareness Week and leading the Kidney Cancer UK Accord project. This last resulted in a formal commission from NHS England to NICE to produce what will ..read more